vTv Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
VTVT$21.00-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of and
Consolidated Balance Sheets
(dollars in thousands, except per share and share data)
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $36,746 | $9,446 |
| Accounts receivable, net | 62 | 102 |
| Prepaid expenses and other current assets | 1,220 | 1,044 |
| Current deposits | 85 | 65 |
| Total current assets | 38,113 | 10,657 |
| Property and equipment, net | 28 | 117 |
| Operating lease right-of-use assets | 125 | 244 |
| Total assets | $38,266 | $11,018 |
| Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $5,027 | $10,242 |
| Current portion of operating lease liabilities | 169 | 169 |
| Current portion of contract liabilities | — | 17 |
| Current portion of notes payable | — | 191 |
| Total current liabilities | 5,196 | 10,619 |
| Contract liabilities, net of current portion | 18,669 | 18,669 |
| Operating lease liabilities, net of current portion | — | 169 |
| Warrant liability, related party | 57 | 110 |
| Warrant liability | 43 | — |
| Total liabilities | 23,965 | 29,567 |
| Commitments and contingencies | ||
| Redeemable noncontrolling interest | — | 6,131 |
| Stockholders’ equity (deficit): | ||
| Class A common stock, $0.01 par value; 200,000,000 shares authorized, 2,612,257 and 2,084,973 shares outstanding as of December 31, 2024 and 2023, respectively | 26 | 21 |
| Class B common stock, $0.01 par value; 100,000,000 shares authorized, and 577,349 outstanding as of December 31, 2024 and 2023 | 6 | 6 |
| Additional paid-in capital | 311,885 | 256,335 |
| Accumulated deficit | (299,718) | (281,042) |
| Total stockholders’ equity (deficit) attributable to vTv Therapeutics Inc. | 12,199 | (24,680) |
| Noncontrolling interest | 2,102 | — |
| Total stockholders’ equity (deficit) | 14,301 | (24,680) |
| Total liabilities, redeemable noncontrolling interest and stockholders’ equity (deficit) | $38,266 | $11,018 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.